Skip to content

Climb Bio, Inc.

CLYM· NasdaqCore metricsCIK 1768446

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -11.31%
Market cap
$638.19M
58.74M shares
Filings
326
—
—
—
-$14.57M
Q3 2026N/M FY25 yoy
-$16.89M
Q3 2026N/M FY25 yoy
-$38.01M
Q3 2026derivedN/M FY25 yoy
-$0.18
Q3 2026N/M FY25 yoy
$39.73M
Q3 2026−59.1% FY25 yoy
$638.19M
—
—
2.8×
-8.55%
—

FY2025 figures · derived

Price

$10.87+471.84%+$8.97past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Total Interest and Dividend Income

$8.13MFY 2024
$8.13M0FY 2023FY 2024
PeriodEndedValueKindSource trail
FY 20242024-12-31$8,132,000reported
FY 20232023-12-31$4,620,000reported

Pharmaceutical preparations

Climb Bio, Inc. is the 171st largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Climb Bio, Inc. · CIK 1768446 · Engraved from SEC EDGAR